Angioedema is a rare and debilitating condition which causes episodes of swelling or edema of the deep layers of skin and mucous membranes. Currently available angioedema treatments include C1 esterase inhibitors and bradykinin receptor antagonists which provide on-demand relief from angioedema attacks. These products differ in their ease of administration and response times making them suitable for varied angioedema conditions. The global market is witnessing increased research activities for development of subcutaneous route of administration and extended half-life products to ensure better patient compliance. The global Angioedema Treatment Market is estimated to be valued at US$ 470.4 Mn in 2023 and is expected to exhibit a CAGR of 4.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the angioedema treatment market is the increasing demand for subcutaneous administration products. Currently available treatments such as C1INH come in intravenous form requiring frequent hospital visits and skilled personnel. However, subcutaneous route enables self-administration at home without medical supervision making it more convenient for patients. Many pharmaceutical companies are focusing on development of subcutaneous C1INH and subcutaneous bradykinin receptor antagonists to cater to this demand. Another trend is increased research for novel drug classes to expand treatment options. Companies are investigating products acting via pathways other than C1INH and bradykinin receptors such as plasma kallikrein inhibitors. This will provide alternative treatment choices based on individual patient needs.
Get more insights on this topic: https://www.coherentmarketinsights.com/market-insight/angioedema-treatment-market-1371
Porter’s Analysis
Threat of new entrants: The threat of new entrants in the Angioedema treatment market is moderate due to the high costs involved in RD of new drugs and the need for regulatory approvals.
Bargaining power of buyers: The bargaining power of buyers is moderate due to the availability of alternative treatment options. However, increased awareness about the effectiveness of new drugs has heightened patients’ expectations.
Bargaining power of suppliers: The bargaining power of suppliers is low due to the presence of many pharmaceutical players and generic drugs manufacturers in this market.
Threat of new substitutes: The threat of new substitutes is low in the Angioedema treatment market as alternative treatment options like epinephrine, antihistamines and corticosteroids are not as effective for managing symptoms.
Competitive rivalry: The competitive rivalry in the market is high due to the presence of many global as well as local players offering generic and branded Angioedema treatment drugs.
Key Takeaways
The global Angioedema treatment market is expected to witness high growth over the forecast period owing to the rising prevalence of Angioedema and increasing awareness about the disease.
Regional analysis: North America dominated the global market in 2020 and is expected to maintain its leading position over the forecast period. This is attributed to the growing number of angioedema cases in the region along with well-developed healthcare infrastructure and higher healthcare spending.
Key players: Key players operating in the Angioedema Treatment Market are Bayer AG, Zoetis Inc., Boehringer Ingelheim GmbH, Merck Co., Inc., Virbac S.A., Ceva Santé Animale, Elanco Animal Health, Bimeda, Aurobindo Pharma Limited, and Teva Pharmaceutical Industries Ltd. Bayer AG and Merck Co. Inc. are some of the leading players in the global angioedema treatment market.
